(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...

Biocon Biologics recently announced that it would manufacture and supply insulin glargine pens to Civica under a multi-year ...

Civica will begin selling a type of insulin on Jan. 1, 2026, although it will not come from the nonprofit drug maker’s ...

Gov. Gavin Newsom says California will begin selling affordable insulin under its own label on Jan. 1, nearly three years ...

LEHI, Utah, Oct. 16, 2025 /PRNewswire/ -- Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price ...

California is on track to become the first state to sell its own insulin. Santa Barbara County Health Pharmacy ...

BRIDGEWATER, N.J. and BENGALURU, India, Oct. 16, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...

California will offer CalRx-branded biosimilar insulin glargine pens for $11 per pen beginning January 1, 2026.

In other news, Lilly announced its investigational oral GLP-1 agent orforglipron outperformed dapagliflozin (Farxiga) for ...

California Gov. Gavin Newsom announces CalRx-branded insulin glargine pens available next Jan. 1, 2026, at a suggested retail price of no more than $55 per five-pack, or $11 per pen, during a news ...

i All doses of orforglipron achieved statistical significance vs. the comparator, with p<0.001 under both the efficacy and treatment-regimen estimands. ii Insulin glargine doses were adjusted per a ...

California will begin offering its own brand of low-cost insulin in 2026, becoming the first state to contract for and sell ...